Eyevensys Overview
- Founded
-
2008
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$11.8M
- Investors
-
12
Eyevensys General Information
Description
Developer of therapeutic proteins intended to address the critical unmet needs in ophthalmology. The company's proteins treat both short and long-term therapeutic outcomes like chronic non-infectious uveitis, degenerative retinal diseases, retinal vascular diseases, and macular oedema, as well as enhance compliance, ocular bioavailability, and tolerability, enabling physicians to treat various eye diseases.
Contact Information
Website
www.eyevensys.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Biopark
- 11 Rue Watt Bat B
- 75013 Paris
- France
+33 01 00 00 00 00
Eyevensys Timeline
Eyevensys Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 04-Aug-2021 | $11.8M | 0000 | 000.00 | Completed | Generating Revenue |
| 4. Later Stage VC (Series B) | 08-Jan-2020 | 000.00 | 000.00 | 00000 | Completed | Generating Revenue |
| 3. Later Stage VC (Series A) | 27-Sep-2016 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 2. Early Stage VC | 11-Apr-2013 | $259K | $2.35M | Completed | Startup | |
| 1. Early Stage VC | 14-May-2012 | $2.09M | $2.09M | 000.00 | Completed | Startup |
Eyevensys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Shares B1 | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Series B | 000,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
| B Shares | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| B Shares | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Series A | 407,297 | $0.011827 | $26.13 | $26.13 | 1x | $26.13 | 14.95% | |
| Ordinary | 21,242 | $0.011827 | $89.08 | $89.08 | 1x | $89.08 | 0.78% |
Eyevensys Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic proteins intended to address the critical unmet needs in ophthalmology. The company's proteins
Drug Discovery
Paris, France
17
As of 2022
0000
00.00
0000-00-00
00000000000
0000
000 00
ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
0000000000000
Ann Arbor, MI
00
As of 0000
000.00
00000000000
000.00
000000
boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000 000000000
Paris, France
00
As of 0000
000.00
0000000000 0
000.00
Add Comparison
Eyevensys Competitors (19)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | 00 | 000.00 | 00000000000 | 000.00 |
| 0000000000000 | Venture Capital-Backed | Paris, France | 00 | 000.00 | 0000000000 0 | 000.00 |
| 0000 000000000000 | Venture Capital-Backed | San Diego, CA | 0 | 0000 | 00000000000 | 0000 |
| 0000000 0000000000 | Formerly VC-backed | Redwood City, CA | 000 | 00000 | 00000000000 | 00000 |
| 0000000 | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 00.000 | 0000000000 0 | 00.000 |
Eyevensys Patents
Eyevensys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2982225-A1 | Electroporation device | Pending | 14-Apr-2015 | 0000000000 | |
| JP-6845154-B2 | Electroporation device | Active | 14-Apr-2015 | 000000000 | |
| EP-3081198-A1 | Elektroporation device for the eye with a support and with a needle electrode | Withdrawn | 14-Apr-2015 | 000000000 | 0 |
| AU-2016247369-B2 | Electroporation device for the eye with a support and with a needle electrode | Active | 14-Apr-2015 | 000000000 | 0 |
| AU-2016247369-A1 | Electroporation device for the eye with a support and with a needle electrode | Granted | 14-Apr-2015 | A61N1/327 |
Eyevensys Executive Team (7)
Eyevensys Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Catherine Boule | Karista (France) | Board Observer | 000 0000 |
| Chahra Louafi | Bpifrance | Board Member | 000 0000 |
| Dominik Escher Ph.D | Pureos Bioventures | Board Member | 000 0000 |
| François Thomas Ph.D | Inserm Transfert | Board Observer | 000 0000 |
| Frank Kalkbrenner Ph.D | Boehringer Ingelheim | Board Member | 000 0000 |
Eyevensys Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Eyevensys Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Korea Investment Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| GF Securities | Investment Bank | Minority | 000 0000 | 000000 0 | |
| Pureos Bioventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Quark Venture | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Bpifrance | Sovereign Wealth Fund | Minority | 000 0000 | 000000 0 |